Receiving rapid access to testosterone therapy reduced feelings of gender dysphoria and led to a clinically significant reduction in depression as well as a 50% reduction in suicidality among transgender and gender diverse adults, according to research being presented Sunday at ENDO 2023, the Endocrine Society’s annual meeting in Chicago, Ill.
“This is the world-first randomized clinical trial supporting the significant benefits of testosterone in reducing gender dysphoria, depression and suicidality in trans individuals desiring commencement of testosterone,” said Brendan Nolan, M.B.B.S., F.R.A.C.P., a Ph.D. candidate at the University of Melbourne (Austin Health) in Melbourne, Australia.
Gender dysphoria occurs when a person feels distressed that their gender identity does not align with the sex assigned at birth. When an individual’s gender identity is not respected and the individual cannot access medical care, it can result in higher psychological problem scores and can raise the person’s risk of committing suicide or other acts of self-harm.
Nolan and colleagues sought to understand the impact of testosterone therapy compared with no treatment on gender dysphoria, depression, and suicidality in trans adults seeking masculinization.
The three-month open-label randomized controlled trial included 64 transgender adults who were able to start testosterone therapy immediately (intervention group) compared with those who were on a standard waiting list of three months prior to beginning testosterone. The purpose of this segmentation was to ensure no person would have to prolong waiting to begin treatment beyond standard care practices.
People who were able to begin treatment immediately showed decreased gender dysphoria and a clinically significant decrease in depression and suicidal ideation compared with study participants on the wait list.
Suicidal ideation resolved in 11 (52%) people with immediate testosterone therapy, compared with 1 (5%) given standard care, according to results from the Patient Health Questionnaire-9.
“Our findings illustrate the significant mental health benefits of early access to testosterone treatment and should provide an impetus for clinicians to ensure timely access to gender-affirming hormone therapy,” Nolan said.
###
About Endocrine Society
Endocrinologists are at the core of solving the most pressing health problems of our time, from diabetes and obesity to infertility, bone health, and hormone-related cancers. The Endocrine Society is the world’s oldest and largest organization of scientists devoted to hormone research and physicians who care for people with hormone-related conditions.
The Society has more than 18,000 members, including scientists, physicians, educators, nurses, and students in 122 countries. To learn more about the Society and the field of endocrinology, visit our site at www.endocrine.org. Follow us on X (formerly Twitter) at @TheEndoSociety and @EndoMedia.
Colleen Williams Senior Communications Manager, Public Relations Phone: (202)-971-3611 [email protected]
Jenni Glenn Gingery Director, Communications and Media Relations Phone: (202)-971-3655 [email protected]
The Endocrine News podcast brings you the latest research and clinical advances from experts in the field, whether you are in your car, office, or out for a run.
Our top-ranked peer-reviewed journals are among the first to publish major developments and discovery milestones.
